阿帕替尼联合替吉奥在晚期食管癌二线治疗中的临床效果及药物不良反应

目的 观察阿帕替尼联合替吉奥在晚期食管癌二线治疗中的临床效果及药物不良反应.方法 回顾性选取2017年1月至2020年1月本院晚期一线治疗失败的60例食管癌患者,依据二线治疗方法将其分为联合治疗组(阿帕替尼联合替吉奥治疗)和单独治疗组(阿帕替尼治疗),各30例.比较两组患者的临床疗效、药物不良反应发生情况、生存质量满意...

Clinical effect and adverse drug reactions of apatinib combined with tegafur gimeracil oteracil potassium in the second-line treatment of advanced esophageal cancer

Objective To observe the clinical effect and adverse drug reactions of apatinib combined with tegafur gimeracil oteracil potassium in the second-line treatment of advanced esophageal cancer.Methods Sixty patients with advanced esophageal cancer who failed first-line treatment in our hospital from January 2017 to January 2020 were retrospectively selected.According to the second-line treatment,the patients were divided into combined treatment group(apatinib combined with tegafur gimeracil oteracil potassium treatment)and single treatment group(apatinib treatment),with 30 cases in each group.The clinical efficacy,adverse drug reactions,satisfaction with quality of life,serum tumor markers levels,survival and recurrence were compared between the two groups.Results The objective remission rate and disease control rate in the combined treatment group were significantly higher than those in the single treatment group(P<0.05).The satisfaction of quality of life in the combined treatment group was significantly higher than that in the single treatment group(P<0.05).After treatment,the levels of serum TSGF,CEA and CA-199 in the two groups were lower than those before treatment,and those in the combined treatment group were lower than the single treatment group(P<0.05).The 1-year survival rate of the combined treatment group was significantly higher than that of the single treatment group,and the recurrence rate was significantly lower than that of the single treatment group(P<0.05).Conclusion The apatinib combined with tegafur gimeracil oteracil potassium in the second-line treatment of advanced esophageal cancer has significantly higher effect than apatinib alone,and there is no significant difference in adverse drug reactions between the two treatment methods.